Virtual Library

Start Your Search

I. Debrix



Author of

  • +

    Poster Display Session (ID 63)

    • Event: ELCC 2017
    • Type: Poster Display Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
    • +

      28P - Impact of a pharmaceutical consultation: Review of a pilot study (ID 382)

      12:30 - 13:00  |  Author(s): I. Debrix

      • Abstract

      Background:
      The development of oral anticancer drug has resulted in several challenges. Prescriptions require a specific monitoring of the patient during his treatment. The objective of this work, resulted from collaboration among health professionals, was to assess the feasibility of setting up a pharmaceutical consultation in department of medical oncology. In addition, we aimed to evaluate the impact of this consultation in reducing prescription errors, drug-drug interactions finding, the early detection of adverse events (AEs) and in the patients’ adherence to both their treatments and the present approach.

      Methods:
      Before the initiation of oral chemotherapy, the oncologist proposed to the patient at participating in a pharmaceutical consultation. Following the patients’ agreement, the pharmacist collected several datas (medical history, community pharmacy medical prescriptions, treating physician) and agreed to an appointment with him. This process allowed to obtain the Best Possible Medication History and establish with the patient the treatment plan. During consultation, the resident assessed the patients’ compliance (with Morisky Scale questionnaire) and informed about the preventive and corrective measures to be implemented in case of AEs. All this datas were related in a specific notebook. A telephone follow-up was proposed to the patient. At last, a report containing all the pharmaco-therapeutic analysis was sent to the oncologist.

      Results:
      The pharmaceutical consultations allowed follow-up of 17 patients. Of the 19 pharmaceutical interventions conducted during the consultations, 94% involved drug-drug interactions. All patients participated to the telephone follow-up. 49 telephones calls allowed the detection of 25 AEs, half of which were referred to other health professionals. For 2 patients, anticancer drug had to be stopped for a bad tolerance finding telephone follow-up. Compliance remained constant over time for all patients. An average score of 9.4/10 was noted by patients for global satisfaction with the activity.

      Conclusions:
      Those results have showed that pharmaceutical consultation could enhance quality management of patients treated by oral anticancer drugs. It highlighted the major interest of this new health professional’s collaboration.

      Clinical trial identification:


      Legal entity responsible for the study:
      Isabelle Debrix

      Funding:
      Hospital Tenon (Paris 20ème)

      Disclosure:
      All authors have declared no conflicts of interest.